Epigral Limited reported record quarterly revenue in the quarter ended 31 March 2026 of Rs 7,360 million (mn), up 17 per cent from Rs 6,310 mn a year earlier. Profit after tax for the quarter was Rs 820 mn compared with Rs 870 mn in the corresponding period last year. The board proposed a final dividend of Rs five per equity share for FY2026. On a sequential basis the company said revenue rose 22 per cent to Rs 7,360 mn from Rs 6,030 mn in the preceding quarter, supported by higher plant utilisation and normalised inventory costs. EBITDA margin improved to 23 per cent from 17 per cent as operational efficiencies lifted absolute EBITDA to Rs 1,690 mn. Quarter-on-quarter profit after tax increased by 109 per cent to Rs 820 mn from Rs 390 mn. The chairman and managing director said the quarter reflected a recovery in volumes after scheduled maintenance and stabilisation of raw material costs, which underpinned margins and realisations. He added that demand recovery that began in November strengthened through the quarter and the company expected this momentum to continue into FY27 subject to global macro conditions. Management noted that the diversified product mix provided resilience amid geopolitical uncertainties. Strategic updates for the year included capital expenditure of Rs 3,940 mn and progress on expansion projects. CPVC resin capacity will reach 150,000 tonnes per annum (TPA) by adding 75,000 TPA and epichlorohydrin capacity will reach 100,000 TPA after an addition of 50,000 TPA. Renewables capacity will reach 38.14 Megawatt (MW) after the scheduled addition of 19.80 MW. For FY2026 revenue was Rs 25,420 mn, down one per cent on lower volumes, while annual EBITDA stood at Rs 5,670 mn with a margin of 22 per cent. Return on capital employed slipped to 16 per cent from 25 per cent owing to lower utilisation and ongoing capital work, and net debt to EBITDA was 0.9 times as at 31 March 2026. The company reiterated its focus on specialty chemicals and integration to drive long-term value.